ALK(SZ:002940) Zheng Quan Shi Bao Wang·2025-07-01 12:54Core Viewpoint - The company, Anglikon, has recently gained significant attention in the market due to its innovative drug business, particularly the ALK-N001 project, which is currently in Phase I clinical trials and received approval in April 2025 [2][3]. Group 1: Company Performance and Market Reaction - Anglikon’s stock price reached a historical high, closing at 40.82 yuan per share, with a trading volume of 6.18 billion yuan and a market capitalization of 82.35 billion yuan [3]. - The company has experienced a decline in net profit, with a 42% drop last year and a 43.63% decrease in the first quarter of this year [3][4]. - Despite the profit decline, the stock has surged by 182% in the first half of the year, with June alone seeing a 146.41% increase, including eight trading halts [4]. Group 2: Research and Development Focus - The company’s increased R&D spending, which reached 231 million yuan (14.99% of revenue), is a key factor in the profit decline, but without this expenditure, net profit would show positive growth [4]. - Anglikon is transitioning towards innovative drug development, collaborating with Shanghai Qinhuali Biotechnology Co., Ltd. to develop the ALK-N001/QHL-1618 product, securing all rights in China [4]. Group 3: Policy Impact on the Industry - Recent favorable policies from the National Healthcare Security Administration and the National Health Commission support the development of innovative drugs, including their inclusion in basic medical insurance and the establishment of a commercial health insurance directory for innovative drugs [3]. - The policies also allow the use of healthcare data for innovative drug research, providing pharmaceutical companies with valuable data services while ensuring data security [3].